Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia

Heart

Volumn 88, Issue 3, 2002, Pages 234-238

  Van Dam, M ^a   Zwart, M ^a   De Beer, F ^b   Smelt, A H M ^b   Prins, M H ^a   Trip, M D ^a   Havekes, L M ^b   Lansberg, P J ^a   Kastelein, J J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTHROPATHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IMPOTENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036720717     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.88.3.234     Document Type: Article

References (48)

1. Type III hyperlipidemia (dysbetalipoproteinemia). The role of apolipoprotein E in normal and abnormal lipoprotein metabolism
2. Type III hyperlipoproteinemia: Quantification, distribution and nature of atherosclerotic coronary arterial narrowing in five necropsy patients
3. The role of apolipoprotein E genetic variants in lipoprotein disorders
4. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III
5. Human apolipoprotein E; the complete amino acid sequence
6. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
7. Genetic control of human apolipoprotein E polymorphism: Comparison of one- and two-dimensional techniques of isoprotein analysis
8. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man
9. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and post-translational modification
10. Familial dysbetalipoprotenemia: Abnormal binding of mutant apolipoprotein E to low-density lipoprotein receptors of human fibroblasts and membranes from liver and adrenals of rats, rabbits and cows
11. Apolipoprotein E: Polymorphism and atherosclerosis
12. Familial hyperlipidemia type III: Deficiency of a specific apolipoprotein (Apo E III) in the very low-density lipoproteins
13. Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III
14. Characterization of a unique human apolipoprotein E variant, associated with type III hyperlipoproteinemia
15. Genetic defects in lipoprotein metabolism: Elevation of atherogenic lipoproteins caused by impaired catabolism
16. Serum lipids, lipoproteins and apolipoprotein E phenotypes in relatives of patients with type III hyperlipidemia
17. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree
18. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146→Gln) allele carriers
19. Apo E variants in patients with type III hyperlipoproteinemia
20. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
21. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipidemia
22. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia
23. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2 (Arg158→Cys), E3-Leiden, and E2(Lys146→Gln), and effects of treatment of simvastatin
24. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil
25. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia
26. Treatment of type III hyperlipoproteinemia with four different treatment regiments
27. Type III hyperlipoproteinemia: Rise in high-density lipoprotein levels in response to therapy
28. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III
29. Effect of fenofibrate treatment on type III hyperlipoproteinemia
30. Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease
31. Gemfibrozil in the treatment of resistant familial hypercholesterolemia and type III hyperlipoproteinemia
32. Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia
33. Preliminary report: Treatment of type III hyperlipoproteinemia with mevinolin
34. Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B
35. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia
36. Effects of statins on triglyceride metabolism
37. Comparison of statins in hypertriglyceridemia
38. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
39. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
40. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
41. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs
42. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs
43. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low-density lipoproteins
44. Separation of VLDL subtractions by density gradient ultracentrifugation
45. A rapid micromethod for apolipoprotein E phenotyping directly in serum
46. Apolipoprotein E genotyping on agarose gels
47. Drug therapy: Patient compliance
48. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia